Published in Int J Gynecol Pathol on January 01, 2008
The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol (2010) 7.27
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol (2011) 5.53
New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol (2008) 3.26
Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol (2009) 2.94
Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol (2008) 2.50
Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol (2011) 1.87
Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch (2012) 1.80
The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. J Pathol (2010) 1.70
Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci U S A (2011) 1.68
Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol (2009) 1.61
Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol (2009) 1.54
The impact of ovulation on fallopian tube epithelial cells: evaluating three hypotheses connecting ovulation and serous ovarian cancer. Endocr Relat Cancer (2011) 1.39
Expression of Cell Competition Markers at the Interface between p53 Signature and Normal Epithelium in the Human Fallopian Tube. PLoS One (2016) 1.37
Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am J Surg Pathol (2011) 1.37
Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol (2010) 1.32
Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study. Int J Cancer (2011) 1.30
CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol (2011) 1.30
Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics. J Oncol (2010) 1.24
A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J Pathol (2014) 1.17
Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol (2012) 1.13
The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma. Clin Exp Metastasis (2012) 1.13
The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention". Clin Obstet Gynecol (2012) 1.13
Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res (2013) 1.09
Insights into endometrial serous carcinogenesis and progression. Int J Clin Exp Pathol (2009) 1.08
Role of CSF-1 in progression of epithelial ovarian cancer. Future Oncol (2009) 1.07
Through the glass darkly: intraepithelial neoplasia, top-down differentiation, and the road to ovarian cancer. J Pathol (2013) 1.06
Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. Mod Pathol (2009) 1.00
Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases. Virchows Arch (2010) 0.99
Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. BMC Cancer (2014) 0.99
Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet? Biomark Med (2009) 0.95
Ki-67 labeling index as an adjunct in the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol (2012) 0.94
Evaluating the progenitor cells of ovarian cancer: analysis of current animal models. BMB Rep (2011) 0.92
Technical challenges and limitations of current mouse models of ovarian cancer. J Ovarian Res (2012) 0.90
Recent advances in the understanding of the pathogenesis of serous carcinoma: the concept of low- and high-grade disease and the role of the fallopian tube. Diagn Histopathol (Oxf) (2008) 0.89
Reliable in vitro studies require appropriate ovarian cancer cell lines. J Ovarian Res (2014) 0.89
IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis. J Exp Clin Cancer Res (2014) 0.88
Precursors of endometrial and ovarian carcinoma. Virchows Arch (2009) 0.88
Carcinomas of Distal Fallopian Tube and Their Association with Tubal Intraepithelial Carcinoma: Do They Share a Common "Precursor" Lesion? Loss of Heterozygosity and Immunohistochemical Analysis Using PAX 2, WT-1, and P53 Markers. ISRN Obstet Gynecol (2010) 0.87
A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population. Front Oncol (2014) 0.86
Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer. Diagn Pathol (2013) 0.85
Ovarian cancer: a clinical challenge that needs some basic answers. PLoS Med (2009) 0.84
Low-grade serous carcinoma of the ovary displaying a macropapillary pattern of invasion. Am J Surg Pathol (2008) 0.83
Expression of ovarian tumour suppressor OPCML in the female CD-1 mouse reproductive tract. Reproduction (2009) 0.83
The disparate origins of ovarian cancers: pathogenesis and prevention strategies. Nat Rev Cancer (2016) 0.81
Opportunistic bilateral salpingectomy during benign gynecological surgery for ovarian cancer prevention: a survey of Gynecologic Oncology Committee of Japan Society of Obstetrics and Gynecology. J Gynecol Oncol (2017) 0.78
Tubal origin of ovarian low-grade serous carcinoma. Am J Clin Exp Obstet Gynecol (2013) 0.78
Dysregulated estrogen receptor signaling in the hypothalamic-pituitary-ovarian axis leads to ovarian epithelial tumorigenesis in mice. PLoS Genet (2014) 0.78
Serous tubal intraepithelial carcinoma, chronic fallopian tube injury, and serous carcinoma development. Virchows Arch (2016) 0.78
Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis. Int J Clin Exp Pathol (2014) 0.78
IMP3 signatures of fallopian tube: a risk for pelvic serous cancers. J Hematol Oncol (2014) 0.77
Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. JCI Insight (2016) 0.76
Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinoma. Int J Gynecol Pathol (2015) 0.76
Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis. Am J Transl Res (2015) 0.76
Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. Cancer Prev Res (Phila) (2016) 0.76
Serous tubal intraepithelial neoplasia: the concept and its application. Mod Pathol (2017) 0.76
Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer. F1000Res (2017) 0.75
Retracted Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis. Am J Transl Res (2016) 0.75
Toward an integrative analysis of the tumor microenvironment in ovarian epithelial carcinoma. Cancer Microenviron (2011) 0.75
Mucinous borderline tumor involving fallopian tube: case report and review of the literature. Int J Clin Exp Pathol (2013) 0.75
The immunomodulating roles of glycoproteins in epithelial ovarian cancer. Front Biosci (Elite Ed) (2012) 0.75
An inconspicuous fallopian-tube carcinoma clinically manifested as a rectovaginal septal tumor: a pitfall for diagnosis and treatment. Int J Clin Oncol (2010) 0.75
LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions. Mod Pathol (2017) 0.75
Loss of calponin h1 confers anoikis resistance and tumor progression in the development of high-grade serous carcinoma originating from the fallopian tube epithelium. Oncotarget (2017) 0.75
Serous Tubal Carcinogenesis: The Recent Concept of Origin of Ovarian, Primary Peritoneal and Fallopian Tube High-Grade Serous Carcinoma. J Obstet Gynaecol India (2017) 0.75
Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev (2005) 12.15
X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell (2006) 7.17
p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell (2007) 6.50
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol (2007) 5.68
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol (2010) 5.59
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell (2003) 4.97
A recurrent mutation in PALB2 in Finnish cancer families. Nature (2007) 4.64
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA (2007) 4.33
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A (2011) 4.15
p63 protects the female germ line during meiotic arrest. Nature (2006) 3.98
The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol (2006) 3.96
Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol (2007) 3.94
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res (2005) 3.41
Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell (2011) 3.36
New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol (2008) 3.26
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol (2007) 3.02
Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection. Cell (2011) 3.00
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell (2010) 2.85
Unique recurrence patterns of cervical intraepithelial neoplasia after excision of the squamocolumnar junction. Int J Cancer (2014) 2.74
Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci U S A (2011) 2.71
A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol (2008) 2.65
Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics (2006) 2.53
Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol (2008) 2.50
The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci U S A (2004) 2.41
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell (2002) 2.24
Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol (2010) 2.18
Endocervical adenocarcinoma in situ with ovarian metastases: a unique variant with potential for long-term survival. Int J Gynecol Pathol (2010) 2.16
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry. J Clin Oncol (2011) 2.13
Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res (2007) 2.12
Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res (2004) 2.05
The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer. Gynecol Oncol (2011) 2.04
Trimodal spectroscopy for the detection and characterization of cervical precancers in vivo. Am J Obstet Gynecol (2002) 2.02
Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev (2002) 1.97
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
NAD(P)H and collagen as in vivo quantitative fluorescent biomarkers of epithelial precancerous changes. Cancer Res (2002) 1.88
Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol (2002) 1.88
Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol (2011) 1.87
Precursors to pelvic serous carcinoma and their clinical implications. Gynecol Oncol (2009) 1.87
Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol (2012) 1.83
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod Pathol (2010) 1.80
Ovarian cancer pathogenesis: a model in evolution. J Oncol (2009) 1.77
BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat (2005) 1.73
The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. J Pathol (2010) 1.70
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res (2006) 1.69
Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. Cancer Res (2009) 1.66
A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol (2011) 1.64
A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A (2012) 1.64
Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol (2002) 1.63
Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance. Int J Gynecol Pathol (2009) 1.62
HPV testing. Visible expectations and hidden realities. Am J Clin Pathol (2003) 1.59
Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Invest (2014) 1.58
PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol (2010) 1.57
Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet (2013) 1.56
Eosinophilic dysplasia of the cervix: a newly recognized variant of cervical squamous intraepithelial neoplasia. Am J Surg Pathol (2004) 1.54
Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci U S A (2011) 1.53
Microglandular hyperplasia: a model for the de novo emergence and evolution of endocervical reserve cells. Hum Pathol (2005) 1.52
14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A (2012) 1.51
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk. Hum Mol Genet (2008) 1.43
BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol (2007) 1.43
Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med (2012) 1.42
Intestinal-type endocervical adenocarcinoma in situ: an immunophenotypically distinct subset of AIS affecting older women. Am J Surg Pathol (2013) 1.42
Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLoS One (2012) 1.42
Meningothelial proliferations in mature cystic teratoma of the ovary: evidence for the common presence of cranially derived tissues paralleling anterior embryonic plate development. An analysis of 25 consecutive cases. Am J Surg Pathol (2010) 1.40
BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research. Breast Cancer Res Treat (2008) 1.40
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia (2010) 1.36
SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal (2009) 1.35
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res (2012) 1.35